Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Excluding Breast Cancer
Interventions: DRUG: TKI258
Sponsor: Novartis Pharmaceuticals